Skip to main content

The Blavatnik Fund for Innovation at Yale

The Blavatnik Fund for Innovation at Yale

Accelerating the translation of early-stage life science research into impactful products. 

Since 2017, Yale has supported 98 projects with over $24 million in direct funding through the Blavatnik Fund for Innovation.

The Blavatnik Fund for Innovation at Yale is a $65 million fund, committed to cultivating and transforming Yale's pioneering research into cutting-edge, life-saving solutions within the realm of life sciences. The Fund is made possible by a generous grant from the Blavatnik Family Foundation in support of the commercialization of Yale faculty applied research and technology in the life sciences. The Fund’s integrated approach combines business expertise, intensive guidance, and essential funding to support innovative, Yale investigator-initiated translational research. Completed projects will be better positioned to positively impact human health through startup advancement, partnerships with industry, major industry-sponsored research agreements, and/or external non-dilutive funding.  

blavatnik applications

We will open application for the Spring 2026 Accelerator Award cycle April 1st.

Blavatnik By The Numbers

Last Updated: 11/14/25

98 

Funded Projects

46

Biotech Ventures Launched

95

Faculty that have received awards including co-PIs (86 Lead PIs)

$24M+ 

Total Awards

$440M 

Raised by Ventures

>350 

Patents associated with Blavatnik-Funded technologies

9

FDA Investigational New Drug (IND) Status

Clinical Trials Initiated

2025 Overview

2025 Highlights

  • $3.4M in awards: 23 awards in 17 therapeutic areas
  • $101M raised across all startups
  • 7 new startups founded

2025 Annual Report

Image
FY25 Fund Metrics